单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）治疗：这一突破性肿瘤治疗方法的临床方面与未来发展
英文原题：Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment.
查看英文原题
Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
TIL（肿瘤浸润淋巴细胞）疗法是一种利用从癌症组织中采集的自体 TIL 来治疗难治性或晚期实体癌的有前景的方法。尽管癌症具有异质性，TIL 疗法仍有可能产生积极的治疗反应，包括完全缓解。经过数十年对淋巴细胞功能、培养/扩增方法、治疗方案以及多项临床试验的研究，TIL 疗法终于达到了可以正式获批用于临床的阶段。TIL 疗法有望作为标准干预措施，在抗癌治疗选择中占据独特地位。为了成功将 TIL 疗法引入临床环境，需要扩大治疗适应证，并建立癌症组织采样和制备的最佳方案及相关临床试验。此外，关于下一代 TIL 疗法的研究已经开始，获批后的真实世界数据将促进并支持进一步的研究。
展开英文摘要原文
Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach for treating refractory or advanced solid cancers by using autologous TILs harvested from cancer tissues. Despite the heterogeneity of cancer, TIL therapy can potentially produce a positive therapeutic response, including complete remission. After decades of research on lymphocyte functions, culture/expansion methods, therapeutic protocols, and multiple clinical trials, TIL therapy has finally reached a stage where it can be formally approved for clinical use.
TIL therapy is expected to hold a unique position among anti-cancer therapeutic options as a standard intervention. To successfully introduce TIL therapy into clinical settings, there is a need to expand therapeutic indications and set up the best protocols for cancer tissue sampling and manufacturing, and related clinical trials.
Moreover, studies on next-generation TIL therapy have already begun, and post-approval real-world data will promote and support further research.
论文信息
- 作者
- Lee H、Kim K、Chung J、Hossain M、Lee HJ
- 第一作者单位
- Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.South Korea
- 通讯作者单位
- Research and Development Center, NeogenTC corp., Seoul, Republic of Korea.South Korea
- 期刊
- BioEssays : news and reviews in molecular, cellular and developmental biology2023 Jul
- 原文标识
- PubMed 37166068 · DOI 10.1002/bies.202200204